Bacteremia Caused by Escherichia coli producing Extended-spectrum Beta-lactamase: a Case-control Study of Risk Factors and Outcomes

Author： Ho Pak-Leung Chan Wai-Ming Tsang Kenneth W. T. Wong Samson S. Y. Young Karl

Publisher： Informa Healthcare

ISSN： 0036-5548

Source： Scandinavian Journal of Infectious Diseases, Vol.34, Iss.8, 2002-08, pp. : 567-573

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

A case-control study was conducted in order to identify the risk factors associated with bloodstream infection caused by Escherichia coli producing extended-spectrum β-lactamase (ESBL) and to determine the outcomes of infected patients. Risk factors associated with ESBL production, according to univariate analysis, included a history of recent hospitalization [odds ratio (OR) 4.3, 95% confidence interval (CI) 2.1-8.9; p < 0.001], severe underlying diseases (OR 15, 95% CI 4.4-51.5; p < 0.001), prior exposure to urinary catheters (OR 8.3, 95% CI 3.2-21.7; p < 0.001) and nosocomial (OR 14.1, 95% CI 6.1-32.8; p < 0.001) or urinary (OR 3.6, 95% CI 1.7-7.4; p < 0.001) origin of the bacteria. Multivariate analysis revealed that severe underlying diseases (OR 31.2, 95% CI 6.7-144; p < 0.001) and nosocomial (OR 16.5, 95% CI 5.6-49; p < 0.001) and urinary origins (OR 7.8, 95% CI 2.6-23.8; p < 0.001) of the bacteria were independently associated with ESBL production in bacteremic E. coli. Crude mortality in case patients was more than twice as high as that in controls (p = 0.04). Production of ESBL increased the risk of inappropriate initial therapy (OR 95.6, 95% CI 27.4-334.2; p < 0.001). Treatment failed in 4/7 case patients treated with ceftazidime to which the isolate was susceptible in vitro. Our findings have implications for the choice of empirical therapy in nosocomial urinary tract infection.

Related content

Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy

By Kang Cheol-In

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 7, 2013-07 ,pp. : 519-525 (7)

Informa Healthcare

Access to resources Recommend Favorite

Cessation of Contact Precautions for Extended-Spectrum Beta-Lactamase (ESBL)–Producing Escherichia coli Seems to be Safe in a Nonepidemic Setting

Infection Control & Hospital Epidemiology, Vol. 38, Iss. 11, 2017-09 ,pp. : 1379-1381 (3)

Cambridge University Press

Access to resources Recommend Favorite

Long-term carriage of extended-spectrum beta-lactamase-producing Escherichia coli

By Alsterlund Rolf Axelsson Carolina Olsson-Liljequist Barbro

Scandinavian Journal of Infectious Diseases, Vol. 44, Iss. 1, 2012-01 ,pp. : 51-54 (4)

Informa Healthcare

Access to resources Recommend Favorite

Extended-spectrum beta-lactamase-producing Escherichia coli in patients with travellers’ diarrhoea

By Tham Johan Odenholt Inga Walder Mats Brolund Alma Ahl Jonas Melander Eva

Scandinavian Journal of Infectious Diseases, Vol. 42, Iss. 4, 2010-03 ,pp. : 275-280 (6)

Informa Healthcare

Access to resources Recommend Favorite

Comparison of community‐onset healthcare‐associated and hospital‐acquired urinary infections caused by extended‐spectrum beta‐lactamase‐producing Escherichia coli and antimicrobial activities

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 7, 2015-07 ,pp. : 766-770 (5)

John Wiley & Sons Inc

Access to resources Recommend Favorite